Geistek Pharmaceuticals is committed to delivering better clinical trial outcomes by providing clinically relevant data through Endpoint Adjudication. We understand the importance of minimizing variation in important trial outcome events and ensuring consistent reporting across regions. Our adaptable and client-oriented team has developed efficient processes to achieve successful results. With established relationships with over 250 experts and key opinion leaders worldwide, we have access to a wealth of therapeutic, clinical research, and endpoint adjudication expertise. We offer a range of services, including contracting adjudication committee members, coordinating committee meetings, developing endpoint reporting forms, and creating project-specific process flows. Our experienced team, led by a management team with 40 years of endpoint adjudication experience, ensures that all endpoints are processed efficiently with clinically relevant data. At Geistek Pharmaceuticals, we employ innovative and reliable technology to support Endpoint Adjudication. Our web-based electronic adjudication system (EAS) is compliant with 21 CFR Part 11 regulations, ensuring data integrity and complete transparency. The EAS improves workflow efficiency, provides an audit trail of activities, and offers secure access 24/7. With features such as data upload from sites, centralized storage of endpoint data, and easy exportability for analysis, our technology streamlines the adjudication process.